Elite in Atopic Dermatitis

Dr. Zoe D. Draelos

Dermatology
2444 N Main St, 
High Point, NC 
Elite in Atopic Dermatitis
2444 N Main St, 
High Point, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Zoe Draelos is a Dermatologist in High Point, North Carolina. Dr. Draelos is rated as an Elite provider by MediFind in the treatment of Atopic Dermatitis. Her top areas of expertise are Acne, Rosacea, Pustules, and Atopic Dermatitis.

Her clinical research consists of co-authoring 272 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 31 articles and participated in 3 clinical trials in the study of Atopic Dermatitis.

Specialties
Dermatology
Licenses
Dermatology in NC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

2444 N Main St, High Point, NC 27262

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
An Evaluation of the Safety and Effectiveness of the N-SWEAT Patch for the Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating
An Evaluation of the Safety and Effectiveness of the N-SWEAT Patch for the Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating
Enrollment Status: Completed
Publish Date: September 07, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Randomized, Double-Blind, Vehicle-Controlled Ascending Doses Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASN008 Topical Gel in Healthy Volunteers and Subjects With Atopic Dermatitis
A Phase 1, Randomized, Double-Blind, Vehicle-Controlled Ascending Doses Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASN008 Topical Gel in Healthy Volunteers and Subjects With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S6G5T-3 in the Treatment of Acne Vulgaris
A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S6G5T-3 in the Treatment of Acne Vulgaris
Enrollment Status: Completed
Publish Date: December 16, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Single-center, Placebo Controlled Study to Investigate the Efficacy of a Nutritional Supplement on Skin Health in Generally Healthy Adults
A Single-center, Placebo Controlled Study to Investigate the Efficacy of a Nutritional Supplement on Skin Health in Generally Healthy Adults
Enrollment Status: Completed
Publish Date: July 09, 2020
Intervention Type: Other, Dietary supplement
Study Phase: Not Applicable
A Multi-center,Double-blind,Randomized,Three-arm,Placebo-controlled,Parallel-group Study, Comparing Dapsone Gel,7.5% (Torrent Pharma) to Aczone® Gel,7.5% and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris
A Multi-center,Double-blind,Randomized,Three-arm,Placebo-controlled,Parallel-group Study, Comparing Dapsone Gel,7.5% (Torrent Pharma) to Aczone® Gel,7.5% and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris
Enrollment Status: Completed
Publish Date: April 02, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: June 04, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea
The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea
Enrollment Status: Completed
Publish Date: June 21, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 11 Less Clinical Trials

272 Total Publications

1% Colloidal Oatmeal Cream/Baby Wash Regimen Improved Atopic Dermatitis in Pediatric Patients From First Use.
1% Colloidal Oatmeal Cream/Baby Wash Regimen Improved Atopic Dermatitis in Pediatric Patients From First Use.
Journal: Journal of drugs in dermatology : JDD
Published: October 02, 2025
Similar Doctors
Distinguished in Atopic Dermatitis
Dr. David S. Rubenstein
Dermatology
Distinguished in Atopic Dermatitis
Dr. David S. Rubenstein
Dermatology
101 Manning Dr, 
Chapel Hill, NC 
 (54.8 miles away)
919-966-4996
Languages Spoken:
English

David Rubenstein is a Dermatologist in Chapel Hill, North Carolina. Dr. Rubenstein is rated as a Distinguished provider by MediFind in the treatment of Atopic Dermatitis. His top areas of expertise are Folliculitis, Atopic Dermatitis, Plaque Psoriasis, and Psoriasis.

Distinguished in Atopic Dermatitis
Dr. James T. Williams
Dermatology
Distinguished in Atopic Dermatitis
Dr. James T. Williams
Dermatology

Tlk Dermatology PLLC

360 Sunset Ave, 
Asheboro, NC 
 (22.7 miles away)
336-625-8410
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Williams is a Dermatologist in Asheboro, North Carolina. Dr. Williams is rated as a Distinguished provider by MediFind in the treatment of Atopic Dermatitis. His top areas of expertise are Nummular Eczema, Atopic Dermatitis, Neurocutaneous Melanosis, and Comedones. Dr. Williams is currently accepting new patients.

Advanced in Atopic Dermatitis
Dr. Joseph L. Jorizzo
Dermatology
Advanced in Atopic Dermatitis
Dr. Joseph L. Jorizzo
Dermatology

Wake Forest University Health Sciences

4614 Country Club Rd, 
Winston Salem, NC 
 (18.2 miles away)
336-716-2255
Languages Spoken:
English
See accepted insurances
Accepting New Patients

My passion throughout my career in dermatology has been to care for adult and pediatric patients with complex medical dermatology problems. My research and publications focus on dermatologic manifestations of internal medical diseases. I also care for patients with common dermatologic problems of skin, hair, nails, and mucous membranes. Dr. Jorizzo is rated as a Distinguished provider by MediFind in the treatment of Atopic Dermatitis. His top areas of expertise are Pyoderma Gangrenosum, Lichen Planus, Cutaneous Lupus Erythematosus (CLE), and Cicatricial Pemphigoid.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Draelos's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile